Takeda Company Profile

What is the competitive landscape for TAKEDA, and what generic alternatives to TAKEDA drugs are available?

TAKEDA has forty-four approved drugs.

There are one hundred and six US patents protecting TAKEDA drugs.

There are one thousand four hundred and thirty patent family members on TAKEDA drugs in fifty-nine countries and one hundred and eighty-eight supplementary protection certificates in nineteen countries.

Summary for Takeda

International Patents:	1430
US Patents:	106
Tradenames:	48
Ingredients:	35
NDAs:	44
Patent Litigation for Takeda:	See patent lawsuits for Takeda
PTAB Cases with Takeda as patent owner:	See PTAB cases with Takeda as patent owner

Drugs and US Patents for Takeda

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	POWDER;ORAL	204734-002	Sep 24, 2014		RX	Yes	Yes	9,023,397		Y
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-004	Nov 23, 2005	AB	RX	Yes	Yes	7,465,465		Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009		DISCN	Yes	No	7,785,627		Y
Takeda Pharms Usa	KAZANO	alogliptin benzoate; metformin hydrochloride	TABLET;ORAL	203414-002	Jan 25, 2013		RX	Yes	Yes	8,288,539			Y
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-006	Jan 25, 2013		DISCN	Yes	No	8,173,663
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-001	Feb 13, 2009	AB	RX	Yes	No	7,361,676		Y

Expired US Patents for Takeda

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	CARBATROL	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	020712-003	Sep 30, 1997	5,912,013
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009	5,965,584
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	6,617,317
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-001	Jan 30, 2009	5,045,321*PED
Takeda Pharms Usa	ADDERALL XR 20	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	021303-002	Oct 11, 2001	6,322,819*PED
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-001	Jan 25, 2013	7,078,381

Paragraph IV (Patent) Challenges for TAKEDA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	5 mg, 10 mg, 15 mgand 20 mg		2017-10-02
	Extended-release Capsules	12.5 mg and 25 mg		2017-08-07
	For Injection	3.5 mg/vial		2008-11-20
	Chewable Tablet	500 mg, 750 mg and 1000 mg		2008-10-27
	Delayed-release Tablets	1.2 g		2009-12-16
	Extended-release Tablets	1 mg, 2 mg, 3 mg and 4 mg		2009-12-29
	Tablets	0.6 mg		2011-12-23
	Delayed-release Orally Disinte	15 mg and 30 mg		2006-12-27
	Tablets	12.5 mg/500 mg and 12.5 mg/1000 mg		2017-01-25
	Delayed-release Capsule	30 mg		2010-11-30
	Tablets	8 mg		2009-07-22
	Extended-release Capsules	37.5 mg and50 mg		2017-08-03
	Tablets	40 mg and 80 mg		2013-02-13
	Capsules	20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg		2011-02-23
	Injection	10 mg/mL		2015-08-25
	Oral Powder	750 mg and 1000 mg		2015-11-25
	Extended-release Tablets	15 mg/1000 mg and 30 mg/1000 mg		2011-09-23
	Tablets	15 mg/500 mg and 15 mg/850 mg		2008-03-06
	Delayed-release Pellets/Capsul	15 mg and 30 mg		2005-12-05
	Tablets	30 mg/2 mg and 30 mg/4 mg		2009-12-22
	Capsule	60 mg		2010-08-25
	Tablets	6.25 mg, 12.5 mg and 25 mg		2017-01-25
	Extended-release Capsules	100 mg and 200 mg		2006-02-02

International Patents for Takeda Drugs

Country	Patent Number	Estimated Expiration
Japan	2011500595
Iceland	7164
Russian Federation	2426530
Canada	2602184
Eurasian Patent Organization	015287
South Korea	101797936

Supplementary Protection Certificates for Takeda Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2178888	122017000025	Germany		PRODUCT NAME: LXAZOMIB UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE UND ESTER WIE LXAZOMIBCITRAT; REGISTRATION NO/DATE: EU/1/16/1094 20161121
2435024	2021C/518	Belgium		PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210
1586571	122014000019	Germany		PRODUCT NAME: VIPIDIA - ALOGLIPTIN; REGISTRATION NO/DATE: EU/1/13/844/001-027 20130919
2498758	CR 2020 00017	Denmark		PRODUCT NAME: METFORMIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; SAXAGLIPTIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SOLVAT DERAF; REG. NO/DATE: EU/1/19/1401 20191113
2178888	17C1011	France		PRODUCT NAME: IXAZOMIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET SES ESTERS TELS QUE LE CITRATE D'IXAZOMIB; REGISTRATION NO/DATE: EU/1/16/1094 20161123
1506211	42/2014	Austria		PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON UND METFORMIN UND EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON; REGISTRATION NO/DATE: EU/1/13/900 (MITTEILUNG) 20140121

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Takeda
• Takeda Pharms Na
• Takeda Pharms Usa